About us

The Cellular and Molecular Therapies (CMT) function within NHS Blood and Transplant (NHSBT) is responsible for the routine provision of stem cells for transplantation across the country and for the development and manufacture of novel advanced cell therapies that fall under Medicines and Healthcare products Regulatory Agency (MHRA) regulations as advanced therapy medicinal products (ATMPs).

CMT operates from seven UK sites, consisting of six Human Tissue Authority (HTA) licensed, Joint Accreditation Committee ISCT-Europe & EBMT (JACIE) accredited cell processing facilities serving regional bone and marrow transplant programmes, three MHRA licensed facilities supporting ATMP manufacture and the Clinical Biotechnology Centre (CBC) at Langford near Bristol preparing GMP-grade DNA plasmids.

Contact us

Email: CMT@nhsbt.nhs.uk

You may also be interested in